This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: August 2nd, 2011 - August 2nd, 2012
This activity was developed for pharmacists and other healthcare professionals practicing in a managed care environment.
Upon completion of this activity, the participant will be able to:
- Discuss recent advances in the treatment and symptom management of multiple sclerosis (MS)
- Describe patient-tailored treatment approaches for modifying the course of the disease and managing symptoms
- Formulate effective management strategies for improving overall outcomes and quality of life for patients with MS
Medical Learning Institute, Inc., is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-11-028-H01-P.
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity for any amount during the past 12 months.
Planners’ and Managers’ Disclosures
Teresa Haile, RPh, MBA, is the MLI reviewer and has nothing to disclose.
Gary M. Owens, MD, is Consultant to Allergan, Auxilium Pharmaceuticals, Eyetech, Johnson & Johnson, Lilly, and OncoMed; has received research grants from Centocor Ortho Biotech and Pfizer; and is on the Advisory Boards of Amgen, Lilly, and Pfizer.
Bruce L. Hughes, MD, has received research grants from and is on the Speakers’ Bureau of Acorda, Bayer, Biogen, EMD Serono, and Pfizer.
Sonya J. Lewis, RPh, MBA, is Advisor to Biogen, Merck Serono, Novartis, and Teva.
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias toward or promotion for any agent discussed in this program should be inferred.
Estimated time to complete activity: 1 hour